SGLT2 inhibitors
50 all articles · 20 / page
Latest news
Tag
Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes
A multinational real-world study found broadly similar cardiovascular effectiveness across individual GLP-1 receptor agonists and SGLT2 inhibitors in metformin-treated type 2 diabetes, including among patients with established cardiovascula
Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure
A validation study developed SABRE, a model that estimates how much SGLT2 inhibitors can reduce heart failure risk in people with type 2 diabetes, helping clinicians target preventive treatment more precisely.
Precision Prescribing of SGLT2 Inhibitors in People With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study
The SABRE model estimates which people with type 2 diabetes may benefit most from SGLT2 inhibitors to prevent heart failure before it develops.
Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure
A validated model, SABRE, estimates who with type 2 diabetes may gain the most heart-failure prevention benefit from SGLT2 inhibitors, enabling more precise, individualized prescribing.
No Clear Winner: Real-World Evidence Shows GLP-1RAs and SGLT2 Inhibitors Deliver Comparable Cardiovascular Benefits in Type 2 Diabetes
A large-scale multinational study of over 1.2 million patients reveals that individual GLP-1 receptor agonists and SGLT2 inhibitors offer broadly similar cardiovascular protection in type 2 diabetes, challenging assumptions about meaningful
SGLT2 Inhibitors Do Not Increase Amputation Risk in Diabetic Foot Ulcer: Study Reveals Significant Mortality Benefit
A retrospective study of 452 diabetic foot ulcer patients found that SGLT2 inhibitor use was not associated with increased amputation risk at 1 year and was linked to significantly lower mortality (1.1% vs 9.2%) and faster wound healing (44
Interaction Between SGLT2 Inhibition and Dietary Sodium: Insights from the CREDENCE Trial Post Hoc Analysis
This post hoc analysis of the CREDENCE trial reveals that low-normal sodium intake increases cardiovascular risk in T2D and CKD, a risk significantly mitigated by canagliflozin, while renal protection remains consistent across sodium intake
Uncoupling Metabolic Benefit from Glycemic Control: Empagliflozin’s Superiority Over Insulin in Beta Cell Preservation
A randomized cross-over trial reveals that empagliflozin enhances beta cell function and insulin sensitivity more effectively than titrated insulin, suggesting benefits beyond simple glucotoxicity relief.
SGLT2 Inhibitors Reduce Gout-Related Medication Burden in Patients with Type 2 Diabetes
A large-scale target trial emulation study demonstrates that SGLT2 inhibitors significantly reduce the initiation of allopurinol and the use of anti-inflammatory medications in patients with comorbid gout and type 2 diabetes, offering a pot
SGLT2 Inhibition and Atrial Fibrillation Recurrence Post-Ablation: Insights from the DARE-AF Randomized Clinical Trial
The DARE-AF trial demonstrates that 10 mg of dapagliflozin for three months does not significantly reduce early arrhythmia recurrence or AF burden following catheter ablation in patients without existing indications for SGLT2 inhibitors.
SGLT2 Inhibitors Offer Potent Protection Against Contrast-Induced Kidney Injury During Coronary Intervention
A large-scale registry study reveals that preprocedural SGLT2 inhibitor use significantly reduces the risk of contrast-associated acute kidney injury in diabetic patients undergoing PCI, suggesting a major shift in peri-procedural managemen
SGLT2 Inhibitors for All? Meta-Analysis Confirms Broad Clinical Benefits Regardless of Diabetes or Albuminuria Levels
A large-scale meta-analysis reveals that SGLT2 inhibitors significantly reduce kidney disease progression, AKI, and hospitalizations in patients with CKD, independent of diabetes status or baseline albuminuria.
SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis
A meta-analysis of over 70,000 participants confirms that SGLT2 inhibitors significantly reduce chronic kidney disease progression regardless of baseline kidney function or albuminuria levels, supporting their use even in patients with Stag
Beyond Insulin: GLP-1 and SGLT2 Inhibitor Combination Therapy Targets Obesity and Kidney Disease in Type 1 Diabetes
A pilot study shows that combining GLP-1 analogues and SGLT2 inhibitors with lifestyle changes significantly reduces body weight and albuminuria in overweight Type 1 diabetes patients with CKD, though glycemic and blood pressure improvement
Beyond Glycemic Control: How SGLT2 and DPP-4 Inhibitor Combinations Rescue the Urinary Microbiome in Type 2 Diabetes
A new study reveals that combining Empagliflozin with Linagliptin reverses urinary dysbiosis in T2D patients, potentially reducing the risk of urogenital infections and improving treatment adherence compared to SGLT2 inhibitor monotherapy.
Beyond Glycemic Control: Empagliflozin/Linagliptin Combination Restores Urinary Microbiota Homeostasis in Type 2 Diabetes
A randomized clinical study demonstrates that while SGLT2 inhibitors alone may induce urinary dysbiosis and increase pathogen risk, combining them with DPP-4 inhibitors restores a healthy urinary microbiota, potentially improving patient co
Precision Medicine Outperforms Standard Albuminuria Thresholds for SGLT2 Inhibitor Selection in Type 2 Diabetes
A new precision medicine model identifies high-benefit patients for SGLT2 inhibitor treatment even when albumin levels appear normal, potentially preventing 10% more kidney failure events than current guidelines that rely solely on albuminu
Dapagliflozin Improves Vascular Stiffness and Cardiorenal Hemodynamics: New Insights from a Randomized Controlled Trial
A 12-week randomized trial demonstrates that dapagliflozin significantly reduces arterial stiffness and modulates fluid dynamics in patients at cardiovascular risk, regardless of diabetes status, providing a mechanistic basis for its broad
SGLT2 Inhibitors Edge Out GLP-1 RAs in Kidney Protection: Insights from a Target Trial Emulation
A nationwide Danish study suggests SGLT2 inhibitors offer superior protection against chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists in patients with type 2 diabetes, particularly for primary prevention.
Challenging the Metformin Monopoly: Insights from the SMARTEST Trial on Early-Stage Type 2 Diabetes Management
The SMARTEST trial investigates whether dapagliflozin should replace metformin as first-line therapy for early type 2 diabetes. Baseline data reveals a surprisingly high microvascular event rate, highlighting the urgent need for early organ